Compare WTRG & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTRG | QGEN |
|---|---|---|
| Founded | 1901 | 1986 |
| Country | United States | Netherlands |
| Employees | 1615 | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.2B |
| IPO Year | 1994 | 1998 |
| Metric | WTRG | QGEN |
|---|---|---|
| Price | $41.71 | $41.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $43.50 | ★ $51.30 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | 3.34% | ★ 5.86% |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $2,474,615,000.00 | N/A |
| Revenue This Year | $1.91 | $8.23 |
| Revenue Next Year | $6.62 | $5.70 |
| P/E Ratio | ★ $18.68 | $24.01 |
| Revenue Growth | ★ 18.62 | N/A |
| 52 Week Low | $36.32 | $38.13 |
| 52 Week High | $42.37 | $57.82 |
| Indicator | WTRG | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 20.02 |
| Support Level | $36.85 | N/A |
| Resistance Level | $42.37 | $49.11 |
| Average True Range (ATR) | 0.93 | 1.00 |
| MACD | 0.13 | -0.76 |
| Stochastic Oscillator | 98.64 | 8.20 |
Essential Utilities is a Pennsylvania-based holding company for US water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Its largest service territory is in Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. It completed the sale of its West Virginia gas utility and the bulk of its nonregulated assets in 2024. Essential shareholders would own a 31% stake in American Water Works if the proposed all-stock merger closes in 2027.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).